Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment
ASCO20 Virtual Scientific Program
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
The ASCO Post Staff
David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castleman, a disease of the lymph nodes, his multiple near-death experiences, and the path that led him to develop a cooperative research effort making a difference for him and other patients with this idiopathic orphan illness.
The ASCO Post Staff
Jeremy L. Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses data from the COVID-19 and Cancer Consortium cohort study, which included patients with active or prior hematologic or invasive solid malignancies, reported across academic and community sites (Abstract LBA110).
The ASCO Post Staff
Leora Horn, MD, of Vanderbilt University, discusses the results of the TERAVOLT study, launched by the Thoracic Cancers International COVID-19 Collaboration. It examined the impact of specific chemotherapy and immunotherapy regimens on hospitalization and risk of death in patients with thoracic malignancies who are also infected with COVID-19 (Abstract LBA111).
The ASCO Post Staff
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy (Abstracts 9506, 9507, 9508).
The ASCO Post Staff
Sara A. Hurvitz, MD, of UCLA’s David Geffen School of Medicine, summarizes four breast cancer studies: KATHERINE, on adjuvant trastuzumab vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer; KAITLIN, on trastuzumab emtansine and pertuzumab vs trastuzumab, pertuzumab, and taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer; TRAIN-2, on neoadjuvant chemotherapy with or without anthracyclines for HER2-positive disease; and PHERGain, on chemotherapy de-escalation using an FDG-PET/CT and pathologic response–adapted strategy in HER2-positive early breast cancer (Abstracts 500, 501, 502, and 503).